Kintara Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaborations
    • Advisors
  • Pipeline
    • Overview
    • VAL-083
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Recent News
    • Events
  • Investors
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Recent News

News & Media

News & Media

  • Press Releases
  • Publications and Abstracts
  • Presentations
  • Recent News
  • Events

Scrip Pharma Intelligence

Scrip Asks… What does 2023 Hold For Biopharma? Part 7: Clinical Trial Trends

Feb 28, 2023

CFO Dive

Biotech CFOs Sharpen Financing Tactics for Lean Times

Jan 18, 2023

Pharmaceutical Technology

As Dianhydrogalactitol moves closer to clinical approval for additional indication, what is the likelihood that the drug will be approved?

Jan 2, 2023

Healio - Hem Onc Today

FDA news: Fast track for glioblastoma drug, breakthrough designation for leukemia therapy

Dec 28, 2022

Precision Oncology News

Kintara Therapeutics Hopes to Fill Treatment Gap in Glioblastoma With VAL-083

Nov 22, 2022

Cancer Therapy Advisor

Novel Agent Plus Radiotherapy Shows Promise in MGMT-Unmethylated Glioblastoma

Nov 19, 2022

Health Professional Radio

Kintara Therapeutics – Seeking New Horizons for Cancer Patients with Novel Therapies

Nov 16, 2022
© 2023 Kintara Therapeutics, Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Legal Information Manage Cookie Preferences